Standard BioTools Inc. announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi? Imaging System. This collaboration is pivotal in the fight against cancer, emphasizing the need for precision medicine strategies and robust technologies that offer critical biological insights to guide treatment decisions.

Imaging Mass Cytometry? is purpose-built to clearly generate and differentiate these insights to help inform clinical outcomes, providing the opportunity to expand access to high-quality data in clinical research. The Hyperion?

XTi Imaging System is a significant advancement in clinical research, offering rapid, robust data acquisition and extended system stability essential for product and drug development. The machine learning process used by Navignostics to discover predictive patterns, and ultimately patient care, demand high throughput, dependable precision and the ability to scale that the Hyperion XTi? can provide.

In clinical studies, Navignostics demonstrated its ability to go from samples to data reporting in under 72 hours, with efforts to further reduce this time. As part of the agreement, Standard BioTools will support the development of Navignostics assays by collaborating on various aspects of protocols and instrument and software features. Additionally, both Navignostics and Standard BioTools plan to leverage their learnings to advance the science of IMC by co-publishing and presenting at scientific conferences in the coming year.

Among key growth strategies for Standard BioTools is enabling new spatial biology applications in translational and clinical research by accelerating the development of turnkey panels, leading with new antibody targets through increased organic investment and partnership.